atai Life Sciences acquires majority stake in Psyber, Inc., to develop Brain Computer Interface-enabled digital therapeutics targeting mental health disorders

April 7, 2021 Articles 9:30 am

atai Life Sciences, a global biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, has acquired a majority stake in Delaware based Psyber, a company dedicated to developing interventions to improve various mental health disorders and induce behavioural changes through brain computer interface (BCI)-enabled digital therapeutics (DTx).

JOIN THE ATAI #INSIGHTNETWORK

Receive the latest news on ATAI and innovations in the space.

Email
submit